Sanofi (EPA:SAN)
France · Delayed Price · Currency is EUR 86.02
+0.13 (0.15%)
Nov 28, 2025, 1:10 PM CET
Revenue by Product
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2010 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2010 - 2019 |
Total Vaccine | 8.30B | Log In | Log In | Log In | Log In | Upgrade |
Total Vaccine Growth | -0.42% | Log In | Log In | Log In | Log In | Upgrade |
Other | 3.21B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Opella Consumer Healthcare | - | Log In | Log In | Log In | Log In | Upgrade |
Opella Consumer Healthcare Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Dupixent | 13.07B | Log In | Log In | Log In | Log In | Upgrade |
Dupixent Growth | 18.42% | Log In | Log In | Log In | Log In | Upgrade |
Total Neurology & Immunology | - | Log In | Log In | Log In | Log In | Upgrade |
Total Neurology & Immunology Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Total Rare Diseases | - | Log In | Log In | Log In | Log In | Upgrade |
Total Rare Diseases Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Total Oncology | - | Log In | Log In | Log In | Log In | Upgrade |
Total Oncology Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Total Rare Blood Disorders | - | Log In | Log In | Log In | Log In | Upgrade |
Total Rare Blood Disorders Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Total Core Assets | - | Log In | Log In | Log In | Log In | Upgrade |
Total Core Assets Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Total Non-Core Assets | - | Log In | Log In | Log In | Log In | Upgrade |
Total Non-Core Assets Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Industrial | - | Log In | Log In | Log In | Log In | Upgrade |
Industrial Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Specialty Care | - | Log In | Log In | Log In | Log In | Upgrade |
Pharma | 32.78B | Log In | Log In | Log In | Log In | Upgrade |
Other | 3.21B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | 3.21B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
EBIT by Product
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2010 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2010 - 2019 |
Other | -2.47B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Pharmaceutical Operating Income | - | Log In | Log In | Log In | Log In | Upgrade |
Pharmaceutical Operating Income Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Vaccine Operating Income | - | Log In | Log In | Log In | Log In | Upgrade |
Vaccine Operating Income Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other Operating Income | - | Log In | Log In | Log In | Log In | Upgrade |
Other Operating Income Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | -2.47B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Consumer Healthcare Operating Income | - | Log In | Log In | Log In | Log In | Upgrade |
Consumer Healthcare Operating Income Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Biopharma Operating Income | 11.29B | Log In | Log In | Log In | Log In | Upgrade |
Biopharma Operating Income Growth | 1.59% | Log In | Log In | Log In | Log In | Upgrade |
Opella Consumer Healthcare (Post-2022 Reporting) Operating Income | - | Log In | Log In | Log In | Log In | Upgrade |
Other (Post-2022 Reporting) Operating Income | 58.00M | Log In | Log In | Log In | Log In | Upgrade |
Other (Post-2022 Reporting) Operating Income Growth | 687.50% | Log In | Log In | Log In | Log In | Upgrade |
Other | -2.47B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2010 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2010 - 2019 |
Other | 3.21B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | 3.21B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
United States | 19.99B | Log In | Log In | Log In | Log In | Upgrade |
United States Growth | 7.33% | Log In | Log In | Log In | Log In | Upgrade |
Europe | 9.03B | Log In | Log In | Log In | Log In | Upgrade |
Europe Growth | -4.61% | Log In | Log In | Log In | Log In | Upgrade |
Rest of World | 12.07B | Log In | Log In | Log In | Log In | Upgrade |
Rest of World Growth | -6.57% | Log In | Log In | Log In | Log In | Upgrade |
Other | 3.21B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |